Analysts expect Imunon Inc to report a Q2 2026 loss per share of $0.94 on negligible revenue, with the current stock price of $1.15 trading significantly below the $11.00 average analyst price target. Investors are primarily focused on the clinical update for IMNN-001, specifically final overall survival data from the Phase 2 OVATION 2 trial in advanced ovarian cancer.
The market is awaiting clarity on the regulatory path and the initiation timeline for a Phase 3 registration study. Furthermore, management’s commentary on the current cash runway will be critical to determine if the company can fund operations through upcoming clinical milestones in 2027.